Market Mover: BioXcel (BTAI) Gains at Midday August 5

Equities Staff  |

BioXcel Therapeutics Inc (NASDAQ: BTAI) has risen $1.14 (7.65%) and sits at $15.88, as of 11:49:01 est on August 5.

92,511 shares exchanged hands.

The Company rose 0.76% over the last 5 days and shares gained 8.13% over the last 30 days.

BioXcel expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on BioXcel visit the company profile.

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

To get more information on BioXcel Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: BioXcel Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

These Stocks are Sending a Signal (like Amazon in 2008)
It Isn’t a Recession Until This Group of Economists Says So
What You Should Know About Europe's Energy Wars
Meatless Meats and Smokeless Smokes
Mixed Wireless Recovery at AT&T, Verizon, T-Mobile: Jeff Kagan
The Strong Dollar Is a Problem for Stocks



Market Movers

Sponsored Financial Content